Overview Of Psoriasis - Global Academy for Medical Education

References
1. Rapp SR, Feldman SR, Exum ML, et al.
Psoriasis causes as much disability as other
major medical diseases. J Am Acad
Dermatol. 1999;41:401-407.
2. Krueger G, Koo J, Lebwohl M, et al.
The impact of psoriasis on quality of life:
Results of a 1998 National Psoriasis
Foundation patient-membership survey.
Arch Dermatol. 2001;137:280-284.
3. Weiss SC, Kimball AB, Liewehr DJ, et al.
Quantifying the harmful effect of psoriasis
on health-related quality of life. J Am Acad
Dermatol. 2002;47:512-518.
4. Singri P, West DP, Gordon KB. Biologic
therapy for psoriasis: The new therapeutic
frontier. Arch Dermatol. 2002;138:657-663.
5. Krueger JG. The immunologic basis for the
treatment of psoriasis with new biologic
agents. J Am Acad Dermatol. 2002;46:1-23.
6. Callis KP, Chadha A, Vaishnaw A, et al.
Reduction of CD45RO + effector T lymphocytes
is not observed in the treatment of
psoriasis with methotrexate. Presented at
the 63rd Annual Meeting of the Society for
Investigative Dermatology; May 15-18,
2002; Los Angeles. Poster 220.
7. Feldman SR, Siegfried EC, Langley R, et al.
Effects of efalizumab (anti-CD11a) on
patient-reported outcomes in patients
with moderate to severe plaque psoriasis.
Presented at Academy 2003 of the
American Academy of Dermatology;
March 21-26, 2003; San Francisco.
Poster 588.
8. Menter A, McCune M, Lynde CW, et al.
Effects of efalizumab (anti-CD11a) on
pruritus in patients with moderate to
severe plaque psoriasis. Presented at
Academy 2003 of the American Academy
of Dermatology; March 21-26, 2003; San
Francisco. Poster 612.
9. Feldman SR, Carey W, Goldman M, et al.
Subcutaneous (SC) efalizumab (anti-
CD11a) significantly improves patientreported
symptoms in patients with moderate
to severe plaque psoriasis. Presented
at Academy 2002 Meeting of the American
Academy of Dermatology; July 31-August
4, 2002; New York. Poster 53.
10. Krueger GG, Papp KA, Stough DB, et al. A
randomized, double-blind, placebo-controlled
phase III study evaluating efficacy
and tolerability of 2 courses of alefacept in
patients with chronic plaque psoriasis.
J Am Acad Dermatol. 2002;47:821-833.
11. Vaishnaw AK, Ticho B. Alefacept is efficacious
in a broad spectrum of patients with
psoriasis, including those with severe disease.
Presented at the 61st Annual Meeting
of the American Academy of
Dermatology; March 21-26, 2003; San
Francisco. Poster P14.
12. Chaudhari U, Romano P, Mulcahy LD,
et al. Efficacy and safety of infliximab
monotherapy for plaque-type psoriasis:
A randomised trial. Lancet. 2001;357:
1842-1847.
13. Gottlieb AB, Li S, Evans R, et al.
Infliximab in the treatment of psoriasis:
Results from the first 10 weeks of the
phase II trial. Presented at the 61st
Annual Meeting of the American
Academy of Dermatology; March 21-26,
2003; San Francisco. Poster 596.
14. Gulliver WP, Brown-Maher T, Tabrizi M,
et al. Low-dose infliximab improves
psoriasis. Presented at the 61st Annual
Meeting of the American Academy of
Dermatology; March 21-26, 2003; San
Francisco. Poster P598.
15. Birbara CA, Coughlin MC. Infliximab in
the treatment of psoriasis. Presented at
the 61st Annual Meeting of the
American Academy of Dermatology;
March 21-26, 2003; San Francisco. Poster
P582.
16. Leonardi C, Gottlieb AB, Zitnik R, et al.
Efficacy and safety of ENBREL‚
(etanercept) in patients with psoriasis:
Results of a phase III study. Presented
at International Investigative Dermatology
2003; April 30-May 4, 2003; Miami
Beach. Poster 0409.
10 Update on the New Biologic Therapies for Psoriasis